Web Analytics

3 Latest Announced Rounds

  • $109,315,123
    Series C

    1 Investors

    Aviation and Aerospace Component Manufacturing
    Apr 23rd, 2024
  • $3,455,284
    Unknown

    4 Investors

    Entertainment Providers
    Apr 23rd, 2024
  • $11,000,000
    Unknown

    1 Investors

    Real Estate
    Apr 23rd, 2024
$2,250.64M Raised in 89 Funding Rounds in the past 7 Days - View All

Funding Round Profile

NextPoint Therapeutics, Inc.

start up
  • 15/02/2024
  • Series B
  • $42,500,000

Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.


Related People

Ivan CheungFounder

Ivan Cheung United States - Scarsdale, New York

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.